Wedbush Reiterates Outperform on Ardelyx, Maintains $9 Price Target
Wedbush analyst Laura Chico reiterates Ardelyx (NASDAQ:ARDX) with a Outperform and maintains $9 price target.
Read original at benzingaStocks · News reference
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Doximity (NYSE:DOCS) stock rose 85.1% to $38.25 during Friday's pre-market session. The market value of their outstanding shares is at $3.7 billion. As per the news, the Q1 earnings report came out
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 7, 2026, 12:05 PM
- Checked
- Aug 7, 2026, 12:05 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
8-K filing — ARDELYX, INC. (ARDX)
Filed: 2026-08-17 AccNo: 0001193125-26-354026 Size: 142 KB Item 8.01: Other Events
Read original at edgarPiper Sandler Maintains Overweight on Ardelyx, Lowers Price Target to $15
Piper Sandler analyst Christopher Raymond maintains Ardelyx (NASDAQ:ARDX) with a Overweight and lowers the price target from $16 to $15.
Read original at benzingaCitigroup Maintains Buy on Ardelyx, Lowers Price Target to $11
Citigroup analyst Yigal Nochomovitz maintains Ardelyx (NASDAQ:ARDX) with a Buy and lowers the price target from $14 to $11.
Read original at benzingaCreative Medical shares are trading higher after the company announced that all patients have now been enrolled and treated across its FDA-cleared ADAPT clinical trial of CELZ-201 / Olastrocel, including the opioid expansion cohort.
Read original at benzingaCreative Medical Technology Says All Patients Enrolled And Treated Across ADAPT Trial Of Olastrocel In Chronic Lower Back Pain, Including FDA-Cleared Opioid Expansion Cohort; Trial Moves To Follow-Up And Phase 3 Planning
Read original at benzinga